These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 27240777)

  • 41. Network mirroring for drug repositioning.
    Park S; Lee DG; Shin H
    BMC Med Inform Decis Mak; 2017 May; 17(Suppl 1):55. PubMed ID: 28539121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug promiscuity: Exploring the polypharmacology potential of 1, 3, 6-trisubstituted 1, 4-diazepane-7-ones as an inhibitor of the 'god father' of immune checkpoint.
    Soremekun OS; Olotu FA; Agoni C; Soliman MES
    Comput Biol Chem; 2019 Jun; 80():433-440. PubMed ID: 31146119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Computational drug repositioning for cancer therapeutics.
    Jiao M; Liu G; Xue Y; Ding C
    Curr Top Med Chem; 2015; 15(8):767-75. PubMed ID: 25732789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-throughput drug repositioning for the discovery of new treatments for Chagas disease.
    Bellera CL; Sbaraglini ML; Balcazar DE; Fraccaroli L; Vanrell MC; Casassa AF; Labriola CA; Romano PS; Carrillo C; Talevi A
    Mini Rev Med Chem; 2015; 15(3):182-93. PubMed ID: 25769967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug repositioning of herbal compounds via a machine-learning approach.
    Kim E; Choi AS; Nam H
    BMC Bioinformatics; 2019 May; 20(Suppl 10):247. PubMed ID: 31138103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology.
    Wathieu H; Issa NT; Byers SW; Dakshanamurthy S
    Curr Pharm Des; 2016; 22(21):3097-108. PubMed ID: 26907947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polypharmacology in Drug Development: A Minireview of Current Technologies.
    Tan Z; Chaudhai R; Zhang S
    ChemMedChem; 2016 Jun; 11(12):1211-8. PubMed ID: 27154144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: geneXpharma.
    Turanli B; Gulfidan G; Arga KY
    OMICS; 2017 Oct; 21(10):584-591. PubMed ID: 29049014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A systems-level analysis of drug-target-disease associations for drug repositioning.
    Rutherford KD; Mazandu GK; Mulder NJ
    Brief Funct Genomics; 2018 Jan; 17(1):34-41. PubMed ID: 28968683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective.
    Li YH; Wang PP; Li XX; Yu CY; Yang H; Zhou J; Xue WW; Tan J; Zhu F
    PLoS One; 2016; 11(11):e0165737. PubMed ID: 27828998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs.
    Bhattarai D; Singh S; Jang Y; Hyeon Han S; Lee K; Choi Y
    Curr Top Med Chem; 2016; 16(19):2156-68. PubMed ID: 26881715
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Computational and experimental advances in drug repositioning for accelerated therapeutic stratification.
    Shameer K; Readhead B; Dudley JT
    Curr Top Med Chem; 2015; 15(1):5-20. PubMed ID: 25579574
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological approach for drug repositioning against cardiorenal diseases.
    Zamami Y; Imanishi M; Takechi K; Ishizawa K
    J Med Invest; 2017; 64(3.4):197-201. PubMed ID: 28954981
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Repurposing medicinal compounds for blood cancer treatment.
    McCabe B; Liberante F; Mills KI
    Ann Hematol; 2015 Aug; 94(8):1267-76. PubMed ID: 26048243
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug repurposing based on drug-drug interaction.
    Zhou B; Wang R; Wu P; Kong DX
    Chem Biol Drug Des; 2015 Feb; 85(2):137-44. PubMed ID: 24934184
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies.
    Xu J; Regan-Fendt K; Deng S; Carson WE; Payne PRO; Li F
    Pac Symp Biocomput; 2018; 23():92-103. PubMed ID: 29218872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug repurposing in cancer.
    Sleire L; Førde HE; Netland IA; Leiss L; Skeie BS; Enger PØ
    Pharmacol Res; 2017 Oct; 124():74-91. PubMed ID: 28712971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
    Cummings JL; Zhong K
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):161-5. PubMed ID: 24502586
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
    Kigondu EM; Wasuna A; Warner DF; Chibale K
    Bioorg Med Chem; 2014 Aug; 22(16):4453-61. PubMed ID: 24997576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Repurposing and repositioning neurosteroids in the treatment of traumatic brain injury: A report from the trenches.
    Stein DG; Sayeed I
    Neuropharmacology; 2019 Mar; 147():66-73. PubMed ID: 29630902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.